About Surien Pharmaceuticals
Surien Pharmaceuticals is a Healthcare company based in Chennai (India) founded in 2001. It manufactures tablets, capsules, syrups and exports pharmaceutical products globally. It operates on a B2B model. Its Indian entity Surien Pharmaceuticals Private Limited reported revenue of ₹16.68 Cr. Surien Pharmaceuticals offers products and services including TRICOBAL OD, INGLIB-M, ACE 1000, PANSafe-DSR, and ATOSKY A 75. Its focus areas include Life Sciences, Pharma Production, Export and Supply and Generic Drugs.
Company details
Surien Pharmaceuticals, based in Chennai, India, is a WHO-GMP and ISO-certified company that produces tablets, capsules, syrups, and other pharmaceutical forms. They utilize advanced equipment and an RD team for quality manufacturing and testing. The company exports to countries like Sri Lanka and supplies products to leading Indian firms on a business-to-business basis, focusing on nutritional and therapeutic solutions.
- Headquarters Chennai, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website surienpharma.in
- Social LinkedIn Facebook Instagram
- Legal Name Surien Pharmaceuticals Private Limited
- Date of Incorporation 19 Apr, 2004
- Jurisdiction Chennai, Tamil Nadu, India
- Annual Revenue₹16.68 Cr
FY 2025 · -18% YoY
- Net Profit₹7.3 Lakh
FY 2025 · 0% margin
- EBITDA₹1.59 Cr
FY 2025 · 10% margin
Associated legal entities of Surien Pharmaceuticals
Surien Pharmaceuticals operates through Surien Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Surien Pharmaceuticals Private Limited CIN U24232TN2004PTC053031 | Active | 19 Apr 2004 | Chennai, Tamil Nadu | ₹16.7 Cr | 25 | 3 | View details |
Products & Services of Surien Pharmaceuticals
Surien Pharmaceuticals offers a comprehensive portfolio of products and services, including TRICOBAL OD, INGLIB-M, ACE 1000, PANSafe-DSR, and ATOSKY A 75.
Restores nutritional deficiency states through oral administration.
Addresses specific medical conditions with targeted formulations.
Manages health issues via effective pharmaceutical delivery.
Provides rapid relief from acid-related disorders.
Supports heart health and reduces ischemic events.
Board of directors of Surien Pharmaceuticals Private Limited (Surien Pharmaceuticals)
Surien Pharmaceuticals Private Limited is the primary company behind Surien Pharmaceuticals. The board of Surien Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Gowri Krishnamoorthy, appointed in 2004. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gowri Krishnamoorthy DIN 02107937 | Director | 21 Apr 2004 | 22 yrs 6 mo | Surien Pharmaceuticals Private Limited |
| Ramasamy Krishnamoorthy DIN 01651885 | Managing Director | 21 Apr 2007 | 19 yrs 6 mo | Surien Pharmaceuticals Private Limited |
| Chathurappan Anbazhagan DIN 08253456 | Whole-time director | 11 Oct 2018 | 8 yrs | Surien Pharmaceuticals Private Limited |
Financials of Surien Pharmaceuticals
Figures of Surien Pharmaceuticals Private Limited, the primary company behind Surien Pharmaceuticals, for FY 2025. Revenue was ₹16.68 Cr (-18% year on year). Net profit was ₹7.3 Lakh (0% margin). EBITDA was ₹1.59 Cr (10% margin). Revenue has grown at a compounded annual rate of -27% over three years and -10% over five years.
- ₹16.68 CrRevenue · FY 2025 · -18% YoY
- ₹7.3 LakhNet profit · 0% margin
- ₹1.59 CrEBITDA · 10% margin
- ₹2.16 CrPaid-up capital
- 25Employees (provident fund records)
- -27%Revenue CAGR, 3 years
- -10%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Surien Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Surien Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Surien Pharmaceuticals
Surien Pharmaceuticals was founded in 2001.
Surien Pharmaceuticals is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
The primary company behind Surien Pharmaceuticals, Surien Pharmaceuticals Private Limited, reported revenue of ₹16.68 Cr for FY 2025, down 18% year on year.
Surien Pharmaceuticals, based in Chennai, India, is a WHO-GMP and ISO-certified company that produces tablets, capsules, syrups, and other pharmaceutical forms. They utilize advanced equipment and an RD team for quality manufacturing and testing. The company exports to countries like Sri Lanka and supplies products to leading Indian firms on a business-to-business basis, focusing on nutritional and therapeutic solutions.
Surien Pharmaceuticals offers TRICOBAL OD, INGLIB-M, ACE 1000, PANSafe-DSR, and ATOSKY A 75.
Surien Pharmaceuticals operates through Surien Pharmaceuticals Private Limited.
The legal entities of Surien Pharmaceuticals currently have 3 directors, including Gowri Krishnamoorthy, Ramasamy Krishnamoorthy, Chathurappan Anbazhagan.